Abstract
The matched-control study failed to show a clinical relevant impact of palifermin on intestinal mucositis, although there was a reduced inflammatory response and less febrile neutropenia among patients who had no bacteraemia.
This is a preview of subscription content, log in via an institution to check access.
References
Sonis ST . Oral mucositis. Anti-Cancer Drugs 2011; 22: 607–612.
Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351: 2590–2598.
Blijlevens N, de Chateau M, Krivan G, Rabitsch W, Szomor A, Pytlik R et al. In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient’s burden. Bone Marrow Transplant 2012; 48: 966–971.
Goldberg JD, Zheng J, Castro-Malaspina H, Jakubowski AA, Heller G, van den Brink MR et al. Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants. Bone Marrow Transplant 2013; 48: 99–104.
Johansson JE, Hasseus B, Johansson P, Eklof C, Ohman D, Stockelberg D . Gut protection by palifermin during autologous haematopoietic SCT. Bone Marrow Transplant 2009; 43: 807–811.
Blijlevens NM, Lutgens LC, Schattenberg AV, Donnelly JP . Citrulline: a potentially simple quantitative marker of intestinal epithelial damage following myeloablative therapy. Bone Marrow Transplant 2004; 34: 193–196.
De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP . Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group. Ann Intern Med 1994; 120: 834–844.
Cancer Therapy Evaluation Program NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 Online Instructions and Guidelines. https://webapps.ctep.nci.nih.gov/webobjs/ctc/webhelp/welcome_to_ctcae.htm . Accessed May 19, 2009.
Costa SF, Barone AA, Miceli MH, van der Heijden IM, Soares RE, Levin AS et al. Colonization and molecular epidemiology of coagulase-negative Staphylococcal bacteremia in cancer patients: a pilot study. Am J Infect Control 2006; 34: 36–40.
Kennedy HF, Morrison D, Kaufmann ME, Jackson MS, Bagg J, Gibson BE et al. Origins of Staphylococcus epidermidis and Streptococcus oralis causing bacteraemia in a bone marrow transplant patient. J Med Microbiol 2000; 49: 367–370.
Ruescher TJ, Sodeifi A, Scrivani SJ, Kaban LB, Sonis ST . The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 1998; 82: 2275–2281.
Herbers AH, Blijlevens NM, Donnelly JP, de Witte TJ . Bacteraemia coincides with low citrulline concentrations after high-dose melphalan in autologous HSCT recipients. Bone Marrow Transplant 2008; 42: 345–349.
Van der Velden WJ, Blijlevens NM, Feuth T, Donnelly JP . Febrile mucositis in haematopoietic SCT recipients. Bone Marrow Transplant 2009; 43: 55–60.
Panoskaltsis-Mortari A, Taylor PA, Rubin JS, Uren A, Welniak LA, Murphy WJ et al. Keratinocyte growth factor facilitates alloengraftment and ameliorates graft-versus-host disease in mice by a mechanism independent of repair of conditioning-induced tissue injury. Blood 2000; 96: 4350–4356.
Ellison CA, Makar BM, Wiseman JM, Gheorghiu I, Taniguchi M, Gartner JG . Palifermin mediates immunoregulatory effects in addition to its cytoprotective effects in mice with acute graft-versus-host disease. J Clin Immunol 2008; 28: 600–615.
Barazzone C, Donati YR, Rochat AF, Vesin C, Kan CD, Pache JC et al. Keratinocyte growth factor protects alveolar epithelium and endothelium from oxygen-induced injury in mice. Am J Pathol 1999; 154: 1479–1487.
Yildirim AO, Muyal V, John G, Müller B, Seifart C, Kasper M et al. Palifermin induces alveolar maintenance programs in emphysematous mice. Am J Respir Crit Care Med 2010; 181: 705–717.
Acknowledgements
We are indebted to Amgen Netherlands for donating an unrestricted grant.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Author contributions
AHEH and NMAB conceived the study, wrote and reviewed the manuscript. JPD and WJFMvdV helped to draft the manuscript. AFJdH performed the statistical analysis.
Rights and permissions
About this article
Cite this article
Herbers, A., van der Velden, W., de Haan, A. et al. Impact of palifermin on intestinal mucositis of HSCT recipients after BEAM. Bone Marrow Transplant 49, 8–10 (2014). https://doi.org/10.1038/bmt.2013.118
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2013.118
- Springer Nature Limited
This article is cited by
-
Anakinra: efficacy in the management of fever during neutropenia and mucositis in autologous stem cell transplantation (AFFECT-2)—study protocol for a multicenter randomized double-blind placebo-controlled trial
Trials (2020)
-
Loss of taste is very common after HCT: taste in wine is very important.
Bone Marrow Transplantation (2020)
-
Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines
Supportive Care in Cancer (2019)
-
RETRACTED ARTICLE: Bismuth adjuvant ameliorates adverse effects of high-dose chemotherapy in patients with multiple myeloma and malignant lymphoma undergoing autologous stem cell transplantation: a randomised, double-blind, prospective pilot study
Supportive Care in Cancer (2017)
-
Palifermin reduces infection rate and hyperfibrinogenemia in patients treated with high-dose chemotherapy based on beam or BU-thiothepa
Bone Marrow Transplantation (2014)